Clinical features and hormonal characteristics in a case of ovarian arrhenoblastoma
- PMID: 8884544
- DOI: 10.1007/BF03349895
Clinical features and hormonal characteristics in a case of ovarian arrhenoblastoma
Abstract
We report a case of a 34-year-old woman affected with ovarian arrhenoblastoma characterized by very high testosterone (T) levels (34.0-60.0 ng/ml; n.v.0.2-0.9) and suppressed gonadotropin levels. The physical examination revealed: severe hirsutism, acne, amenorrhea and other virilization signs. Basal hormonal evaluation also showed a markedly elevated 17-hydroxyprogesterone (17-OHP) and a mild delta 4 Androstenedione (A) and dehydroepiandrosterone sulfate (DHEAs) increase. ACTH test induced only slight changes in androgen secretion. By contrast, dexamethasone test greatly decreased A and DHEAs whereas T levels were only partially suppressed. Moreover, hCG test was clearly stimulatory for T and A. Suppressed gonadotropin levels did not respond to LHRH stimulation. The removal of the neoplasia was followed by normalization of T levels and increase of serum gonadotropins with subsequent restoration of a normal responsiveness to LHRH and resumption of an ovulatory menstrual cycle. This observation suggests that the high T levels played a primary role in the pathogenesis of the gonadotropin suppression and anovulation. Recovery of acne was complete whereas hirsutism score was reduced but still elevated after one year. This may be due to postoperative A and DHEAs levels slightly above the normal range, indicating the presence of adrenal hyperandrogenism.
Similar articles
-
Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist?Metabolism. 1997 Aug;46(8):902-7. doi: 10.1016/s0026-0495(97)90077-9. Metabolism. 1997. PMID: 9258272
-
Endocrine studies on ovarian androblastomas (Sertoli-Leydig tumors).J Endocrinol Invest. 1984 Dec;7(6):615-22. doi: 10.1007/BF03349495. J Endocrinol Invest. 1984. PMID: 6099378
-
The hormone pattern in a case of arrhenoblastoma.Eur J Pediatr. 1981 May;136(2):203-6. doi: 10.1007/BF00441925. Eur J Pediatr. 1981. PMID: 6262084
-
Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.Clin Endocrinol (Oxf). 1994 Nov;41(5):571-6. doi: 10.1111/j.1365-2265.1994.tb01820.x. Clin Endocrinol (Oxf). 1994. PMID: 7828344
-
Diagnosis and resection of an oral contraceptive-suppressible Sertoli-Leydig cell tumor with preservation of fertility and a 7-year follow-up.Obstet Gynecol. 1989 May;73(5 Pt 2):901-5. Obstet Gynecol. 1989. PMID: 2523030 Review.
Cited by
-
Sertoli-Leydig cell tumor - a rare androgen secreting ovarian tumor in postmenopausal women. Case report and review of literature.J Cell Mol Med. 2003 Oct-Dec;7(4):461-71. doi: 10.1111/j.1582-4934.2003.tb00249.x. J Cell Mol Med. 2003. PMID: 14754515 Free PMC article. Review.
-
Changing pattern of gonadotropins in a patient with an adrenal-androgen secreting tumor.Clinics (Sao Paulo). 2011;66(2):355-7. doi: 10.1590/s1807-59322011000200029. Clinics (Sao Paulo). 2011. PMID: 21484059 Free PMC article. No abstract available.
-
Luteinizing hormone pulsatility in patients with major ovarian hyperandrogenism.J Endocrinol Invest. 2007 Sep;30(8):636-46. doi: 10.1007/BF03347443. J Endocrinol Invest. 2007. PMID: 17923794
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical